Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism EZH2 inhibitors(Histone-lysine N-methyltransferase EZH2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationSpecial Review Project (CN), Breakthrough Therapy (CN), Priority Review (CN) |
Molecular FormulaC32H44N4O4 |
InChIKeyYLZVNQZYAYVUCW-UHFFFAOYSA-N |
CAS Registry2098545-98-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Peripheral T-Cell Lymphoma | NDA/BLA | CN | 11 Oct 2024 | |
Advanced Prostate Carcinoma | Phase 2 | CN | 06 Sep 2024 | |
Follicular Lymphoma | Phase 2 | CN | 01 Apr 2024 | |
Refractory Classic Hodgkin Lymphoma | Phase 2 | CN | 14 Jun 2023 | |
Castration-Resistant Prostatic Cancer | Phase 2 | US | Treeline Biosciences, Inc.Startup | 12 Feb 2023 |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 01 Sep 2020 | |
B-Cell Lymphoma | Phase 2 | CN | 01 Sep 2020 | |
T-Cell Lymphoma | Phase 1 | CN | 01 Jul 2022 | |
Non-Hodgkin Lymphoma | Phase 1 | US | 30 Jan 2022 | |
Metastatic castration-resistant prostate cancer | Preclinical | CN | 20 Nov 2018 |
NCT04407741 (ASCO2023) Manual | Phase 1 | 32 | (tfwqutwyla) = SHR2554 350mg bid plus SHR-1701 30mg/kg q3w tqfaheourd (vpukfjkvbv ) View more | Positive | 31 May 2023 | ||
NCT03603951 (pubmed) Manual | Phase 1 | 113 | (vjdqxkaeuz) = dirtwvzjev whnpxuczkj (bqeslwaoyq ) View more | Positive | 01 Jul 2022 | ||
Phase 1 | 113 | (eufinzadaa) = uodhztatke zlqbopwymz (sikfbchkcm, 42.1 - 73.7) View more | - | 02 Jun 2022 |